Douglas Barthold1, Geoffrey Joyce2, Patricia Ferido3, Emmanuel F Drabo4, Zachary A Marcum1, Shelly L Gray1, Julie Zissimopoulos3. 1. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle, WA, USA. 2. School of Pharmacy, Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA. 3. Price School of Public Policy, Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA. 4. Health Policy and Management Department, Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND: Four prescription drugs (donepezil, galantamine, memantine, and rivastigmine) are approved by the US FDA to treat symptoms of Alzheimer's disease (AD). Even modest effectiveness could potentially reduce the population-level burden of AD and related dementias (ADRD), especially for women and racial/ethnic minorities who have higher incidence of ADRD. OBJECTIVE: Describe the prevalence of antidementia drug use and timing of initiation relative to ADRD diagnosis among a nationally representative group of older Americans, and if there are disparities in prevalence and timing by sex and race/ethnicity. METHODS: Descriptive analyses and logistic regressions of Medicare claims (2008-2016) for beneficiaries who had an ADRD or dementia-related symptom diagnosis, or use of an FDA approved drug for AD. We investigate prevalence of use and timing of treatment initiation relative to ADRD diagnosis across time and beneficiary characteristics (age, sex, race/ethnicity, socioeconomic status, comorbidities). RESULTS: Among persons diagnosed with ADRD or related symptoms, 33.3% used an approved drug over the study period. Odds of use was higher among Whites than non-Whites. Among ADRD drug users, 40% initiated use within 6 months of the initial ADRD or related symptoms diagnosis, and 16% initiated prior to a diagnosis. We observed disparities by race/ethnicity: 28% of Asians, 24% of Hispanics, 16% of Blacks, and 15% of Whites initiated prior to diagnosis. CONCLUSIONS: The use of antidementia drugs is relatively low and varies widely by race/ethnicity. Heterogeneity in timing of initiation and use may affect health and cost outcomes, but these effects merit further study.
BACKGROUND: Four prescription drugs (donepezil, galantamine, memantine, and rivastigmine) are approved by the US FDA to treat symptoms of Alzheimer's disease (AD). Even modest effectiveness could potentially reduce the population-level burden of AD and related dementias (ADRD), especially for women and racial/ethnic minorities who have higher incidence of ADRD. OBJECTIVE: Describe the prevalence of antidementia drug use and timing of initiation relative to ADRD diagnosis among a nationally representative group of older Americans, and if there are disparities in prevalence and timing by sex and race/ethnicity. METHODS: Descriptive analyses and logistic regressions of Medicare claims (2008-2016) for beneficiaries who had an ADRD or dementia-related symptom diagnosis, or use of an FDA approved drug for AD. We investigate prevalence of use and timing of treatment initiation relative to ADRD diagnosis across time and beneficiary characteristics (age, sex, race/ethnicity, socioeconomic status, comorbidities). RESULTS: Among persons diagnosed with ADRD or related symptoms, 33.3% used an approved drug over the study period. Odds of use was higher among Whites than non-Whites. Among ADRD drug users, 40% initiated use within 6 months of the initial ADRD or related symptoms diagnosis, and 16% initiated prior to a diagnosis. We observed disparities by race/ethnicity: 28% of Asians, 24% of Hispanics, 16% of Blacks, and 15% of Whites initiated prior to diagnosis. CONCLUSIONS: The use of antidementia drugs is relatively low and varies widely by race/ethnicity. Heterogeneity in timing of initiation and use may affect health and cost outcomes, but these effects merit further study.
Entities:
Keywords:
Acetylcholinesterase inhibitors; Alzheimer’s disease and related dementias; disparities; donepezil; galantamine; memantine; rivastigmine
Authors: M X Tang; P Cross; H Andrews; D M Jacobs; S Small; K Bell; C Merchant; R Lantigua; R Costa; Y Stern; R Mayeux Journal: Neurology Date: 2001-01-09 Impact factor: 9.910
Authors: Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant Journal: Alzheimers Dement Date: 2018-12-13 Impact factor: 21.566
Authors: Noll L Campbell; Anthony J Perkins; Sujuan Gao; Todd C Skaar; Lang Li; Hugh C Hendrie; Nicole Fowler; Christopher M Callahan; Malaz A Boustani Journal: J Am Geriatr Soc Date: 2017-03-14 Impact factor: 5.562
Authors: Julie M Zissimopoulos; Bryan C Tysinger; Patricia A St Clair; Eileen M Crimmins Journal: J Gerontol B Psychol Sci Soc Sci Date: 2018-04-16 Impact factor: 4.942
Authors: Maria Pisu; Roy C Martin; Liang Shan; Giovanna Pilonieta; Richard E Kennedy; Gabriela Oates; Young-Il Kim; David S Geldmacher Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Jamie A Browning; Chi Chun Steve Tsang; Rose Zeng; Xiaobei Dong; Joseph Garuccio; Jim Y Wan; Marie A Chisholm-Burns; Christopher K Finch; Jack W Tsao; Junling Wang Journal: Curr Med Res Opin Date: 2022-08-09 Impact factor: 2.705
Authors: Maria Mora Pinzon; Jody Krainer; Tamara LeCaire; Stephanie Houston; Gina Green-Harris; Nia Norris; Stacy Barnes; Lindsay R Clark; Carey E Gleason; Bruce P Hermann; Helen Ramon; Will Buckingham; Nathaniel A Chin; Sanjay Asthana; Sterling C Johnson; Art Walaszek; Cynthia M Carlsson Journal: J Am Geriatr Soc Date: 2022-04-01 Impact factor: 7.538
Authors: Douglas Barthold; Zachary A Marcum; Shelly L Gray; Julie Zissimopoulos Journal: Pharmacoepidemiol Drug Saf Date: 2020-08-27 Impact factor: 2.732